Hyderabad India-headquartered Excelra, a global Data and Analytics provider for Life Science organizations, announced a strategic majority investment in Anlitiks, aechnology company in the value and evidence domain.
This move reinforces Excelra’s footprint into the Health Economics and Outcomes Research (HEOR) and Real-World Evidence (RWE) analytics area. The deal will expedite drug discovery and commercialization by combining deep scientific domain expertise with technology and analytics solutions.
Anlitiks’ RapidAnalyzer™, is a flexible, data-agnostic platform that captures the entire lifecycle of HEOR/RWE from hypothesis, data integration, analysis, visualization to a research report. RapidAnalyzer™ changes the competitive landscape by drastically reducing the time taken to gain valuable insights on large-scale data from months to just a matter of weeks.
Kannan Rajagopalan founder of Antiliks said “Our vision is to be a technology-enabled disruptive force in generating rapid actionable insights for the Life Science industry using real-world data. Excelra’s focus areas dovetail perfectly with our growth strategy, making it the beginning of an exciting journey.”
Last updated: December 26th, 2025
